StudyFinder

Search Results

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

426 Study Matches

Increasing HPV vaccination coverage among pediatric, adolescent, and young adult (PAYA) cancer survivors: A multilevel intervention

The purpose of this research is to test the efficacy of different interventions to increase vaccination against human papillomavirus (HPV). Survivors of childhood, adolescent and young adult cancers are at increased risk of developing HPV-associated secondary cancers, but have lower HPV vaccination coverage compared to the general population. Interventions which are found to be successful in this study will be incorporated into future survivorship care to improve adherence to recommend preventive healthcare practices. All research procedures will be conducted remotely (e.g. online).

Principal Investigator: Deanna Teoh
Age Group: Not specified
This study is NOT accepting healthy volunteers
IRB Number: STUDY00013006
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• current patient in the University of Minnesota CCSP clinic or the Children's Minnesota Long-Term Follow-up (LTFU) Program clinic
• seen in the CCSP clinic who do not have a history of cancer but who have received immunosuppressive therapy or HSCT for treatment of a hematologic disorder
• survivor of childhood cancer (diagnosed with cancer at age 25 years or younger) who is currently 18-26 years of age OR a caregiver of a survivor of childhood cancer who is currently 9-17 years of age
• at least 6 months post-treatment (current treatment for graft-versus-host disease allowed)
• no previous HPV vaccination or incomplete HPV vaccination
• people who are unsure of their HPV vaccination status and are unable to find vaccination records (study staff will review)
Exclusion Criteria:

• previously completed HPV vaccination series
• unable to read and write in English
• pregnant or plans to become pregnant in the next year
• currently receiving treatment for cancer or hematologic disorder or plan for treatment in next 12 months
• immediate hypersensitivity reaction to any vaccine component (study staff will review)
Conditions: Cancer, Children's Health
Keywords: Clinics and Surgery Center (CSC), cancer survivors, HPV, vaccination
I'm interested
Share via email
See this study on ClinicalTrials.gov

An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination with Pembrolizumab Versus Chemotherapy in Subjects with Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma that Expresses HER2 (IHC 1+ and Greater)

We’re studying disitamab vedotin to find out what its side effects are and if it works for urothelial cancer when given with pembrolizumab. We want to see if these drugs work better together than the available approved treatments.

Principal Investigator: Gautam Jha
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: STUDY00018433
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• confirmed locally advanced unresectable or metastatic urothelial cancer (UC) including that originating from the renal pelvis, ureters, bladder, or urethra
• able to receive cisplatin- or carboplatin-containing chemotherapy
• able to walk and do all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours
• see link to clinicaltrials.gov for complete inclusion and exclusion criteria
Exclusion Criteria:

• history of or active autoimmune disease that has required systemic treatment in the past 2 years
• prior solid organ or bone marrow transplantation
• pleural effusion or ascites with symptoms or requiring symptomatic treatment
Conditions: Cancer
Keywords: Urothelial Carcinoma
I'm interested
Share via email
See this study on ClinicalTrials.gov

Brain Training for Substance Use Disorders

Participants play games designed to train visual attention towards natural, non-drug-related scenarios. A biofeedback loop between gameplay and an electroencephalogram (EEG) system monitors game performance and guides game difficulty.

Principal Investigator: Justin Anker
Age Group: 18 years and over
This study is also accepting healthy volunteers
IRB Number: SITE00001900
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• 18 to 65 years of age
• admitted to Fairview's Lodging Plus program for chemical dependency treatment with opioid use being the primary reason
• able to read at a minimum of a 6th grade reading level
• willing to provide own contact information for follow-up visit(s)
• for HEALTHY CONTROLS: 18 to 65 years old, able to read at a minimum of a 6th grade reading level, and willing to provide own contact information for follow-up visit(s)
Exclusion Criteria:

• pregnancy
• history of serious neurological illness (e.g., Chronic seizure disorder, Wernicke-Korsakoff Syndrome, Epilepsy, Any history of seizures)
• unable to see text and photos clearly on a computer display
• current or previous problems using opioids, other prescription (prescribed or not prescribed) or illicit drugs
• regular nicotine user (e.g., cigarette smoker, e-cig user) within the past 12 months and
• unwillingness to change hairstyle (e.g., braids, pony tails, dreadlocks) or remove wig to accommodate application of the EEG headset, if necessary
Conditions: Brain & Nervous System, Mental Health & Addiction
Keywords: biofeedback, brain games, brain training, neurofeedback, noninvasive eeg, substance use, wearables
I'm interested
Share via email
See this study on ClinicalTrials.gov

ABATE-IP-18: A Phase 1b, Multi-center Study of IV Gallium Nitrate in Patients with Cystic Fibrosis who are Colonized with Nontuberculous Mycobacteria (The ABATE Study) (ABATE)

The purpose of this research study is to test the safety of giving two separate 5-day infusions (starting on Day 1 and again around Day 15) through a vein with a drug called gallium nitrate. Laboratory tests suggest that this drug may be able to fight Nontuberculous Mycobacteria (NTM) infections

Principal Investigator: Joanne Billings
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: STUDY00020585
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• diagnosis of cystic fibrosis
• persistent Nontuberculous Mycobacterium lung infection (NTM)
• able to expectorate sputum
• enrolled in the CFF Patient Registry
• see link to clinicaltrials.gov for complete inclusion & exclusion criteria
Exclusion Criteria:

• history of solid organ or hematological transplantation
• current diagnosis of osteoporosis
• women who are pregnant or breast feeding
• men and women who are unwilling to practice a medically acceptable form of contraception
Conditions: Rare Diseases, Breathing, Lung & Sleep Health
Keywords: CF, Cystic Fibrosis, Nontuberculous Mycobacterium Infection, NTM

MT2023-28: A Phase 1 Basket Study Evaluating the Safety and Feasibility of T-Plex, Autologous Customized T Cell Receptor-Engineered T Cells Targeting Multiple Peptide/HLA Antigens in Participants with Antigen-positive Locally Advanced (Unresectable) or Metastatic Solid Tumors: PLEXI-T(TM)

This study aims to find out if investigational new drugs, TSC-204-A0201, TSC-204- A0702 and TSC-200-A0201, can help your cancer better than the standard of care (SOC) that are currently available and accepted by medical experts as a proper treatment. T-cells are part of the immune system and develop from stem cells in the bone marrow. They help protect the body from infection and fight cancer. For this study, T-cells will be collected through a process called leukapheresis. T-cells from your leukapheresis will be used to make the study drugs specifically tailored for you and your immune system. The purpose of the study is to learn if the study drugs are safe and effective in treating your type of cancer.

Principal Investigator: Benjamin Manning
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: STUDY00019932
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• previously received at least one line of standard systemic therapy for advanced or metastatic cancer and have either progressed, recurred, or were intolerant to the previous treatment
• unable to do physically strenuous activity but able to walk and carry out work of a light or sedentary nature, e.g., light house work, office work
• women must not be pregnant or breastfeeding
• see link to clinicaltrials.gov for complete inclusion and exclusion criteria
Exclusion Criteria:

• known active CNS metastases
• systemic steroid therapy
• history of a bleeding disorder
• active, uncontrolled bacterial, fungal, or viral infection
• prior history or have another cancer
Conditions: Cancer
Keywords: Clinics and Surgery Center (CSC), advanced cancer, cancer, metastatic cancer, solid tumors
I'm interested
Share via email
See this study on ClinicalTrials.gov

Effects of relighting on smoke toxicant deliveries and subjective smoking measures

The purpose of this study is to understand how relighting cigarettes affects the level of toxicants inhaled during smoking, compared to smoking non-relit cigarettes.

Principal Investigator: Irina Stepanov
Age Group: 21 years and over
This study is also accepting healthy volunteers
IRB Number: STUDY00021107
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• at least 21 years old
• smoking at least 5 cigarettes/day for at least 1 year
• engaging in relighting behavior – extinguishing, saving, and later relighting unfinished cigarette butts
• no attempts to quit smoking in the past month nor intentions to quit in the next month
• systolic blood pressure < 160, diastolic blood pressure < 100 and heart rate < 105 bpm
• see link to clinicaltrials.gov for complete inclusion and exclusion criteria
Exclusion Criteria:

• current or recent alcohol or drug abuse problems, use of substances of abuse (other than marijuana due to high prevalence of co-use) within the past month
• women who are planning to become pregnant, pregnant or breastfeeding
Conditions: Cancer, Community Health
Keywords: Cigarette, Nicotine Dependence, Smoking, Tobacco

MT2012-11C: Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

The primary purpose of this study is to record outcomes and patient characteristics in the Masonic Cancer Center and BMT databases for patients who are undergoing an allogeneic (donor) hematopoietic stem cell transplant. The data will be analyzed for transplant “milestones” such as time to blood count recovery (engraftment) and how patients are doing at 3 months and 6 months after the transplant. Participation in this study will not alter treatment or medical care. All information for this study will be collected from medical records.

Principal Investigator: Troy Lund
Age Group: Not specified
This study is NOT accepting healthy volunteers
IRB Number: 1207M17641
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• up to 55 years old
• diagnosis of any disease for which a second or greater hematopoietic stem cell transplant (HSCT) is needed
• see link to clinicaltrials.gov for complete inclusion and exclusion criteria
Exclusion Criteria:

• women who are pregnant or breastfeeding
• active, uncontrolled infection
• HIV positive
Conditions: Blood Disorders
Keywords: Hematologic Disorders, Hemoglobinopathies, HSCT, Immunodeficiencies, Stem Cell Transplant, Clinics and Surgery Center (CSC)
I'm interested
Share via email
See this study on ClinicalTrials.gov

Biorepository to Support ALS Research in Minnesota

The purpose of the study is to establish and maintain a biorepository of tissue and biospecimen samples relevant to Amyotrophic Lateral Sclerosis (ALS) research. We will obtain, store, and catalogue peripheral blood mononuclear cells (PBMCs), blood and blood components, skin punch biopsy samples, and cerebral spinal fluid (CSF) from people living with ALS, linked to clinical datasets, to advance ALS research.

Principal Investigator: David Walk
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: STUDY00022317
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• people living with ALS: people with a confirmed diagnosis of ALS
• Controls: people who have a neurological disorder other than ALS for which a comparison will assist in medical discovery Healthy controls: Individuals without ALS or other neurological disorders
Exclusion Criteria:

• age less than 18 or greater than 90
Conditions: Brain & Nervous System, Rare Diseases, Rare Diseases
Keywords: ALS, amyotrophic lateral sclerosis, Clinics and Surgery Center (CSC)
I'm interested
Share via email

UAZ21-07-01 Metformin Study

In this study we will test whether metformin works in preventing oral cancer in patients with oral leukoplakia (white patches) or erythroplakia (red patches). Metformin is in a class of drugs called biguanides. Metformin helps to control the amount of glucose (sugar) in the blood. It decreases the amount of glucose patients absorb from food and the amount of glucose made by the liver. Metformin also increases the body's response to insulin, a natural substance that controls the amount of glucose in the blood. This trial may help researchers determine if metformin can stop changes in the mouth that are related to pre-cancer growths in the mouth.

Principal Investigator: Frank Ondrey
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: SITE00001629
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• at least 21 years old
• diagnosis of oral leukoplakia or erythroplakia (white or red patches in the mouth)
• current and former smokers (>= 5 packs in the lifetime)
• willing to use adequate contraception for the duration of study participation
• able to take oral medication
• understand English or Spanish
• see link to clinicaltrials.gov for complete inclusion criteria
Exclusion Criteria:

• people with diabetes who are being treated with insulin or an anti-diabetic medication
• history of diabetic ketoacidosis
• Hemoglobin A1c (HbA1c) > 8%
• history of chronic alcohol use
• women who are pregnant or breastfeeding
• see link to clinicaltrials.gov for complete exclusion criteria
Conditions: Cancer, Prevention & Wellness
Keywords: Clinics and Surgery Center (CSC), Erythroplakia, Oral Leukoplakia
I'm interested
Share via email
See this study on ClinicalTrials.gov

NEA Research Lab

This keystone study will invite adolescents into a 2-semester creative arts / science program, with arts activities taking place at the Masonic Institute of the Developing Brain (MIDB).

Principal Investigator: Kathryn Cullen
Age Group: Up to 18 years old
This study is also accepting healthy volunteers
IRB Number: STUDY00015930
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• age 13-17
• adolescents and at least one parent / guardian must be able to speak English
Exclusion Criteria:

• unable to have a MRI (e.g. claustrophobia, braces)
• neurodevelopmental disorder (e.g. intellectual disability, severe autism)
• major medical and/or neurological illness
• pregnancy when starting the study
Conditions: Children's Health, Mental Health & Addiction
Keywords: Adolescents, Arts, Creativity
Visit study website
I'm interested
Share via email

Pilot study_Jaw Muscle Metabolic and Brain-Derived Phenotypes of Chronic TMD Pain

The goal of this study is to learn more about a new way of gathering information about a person’s jaw muscle pain – taking scans of the jaw muscles while a person bites down on a special device. It is hoped that the information learned in this study will help the study team to design a bigger study on this new way of learning about jaw muscle pain, which may lead to better, more individualized treatments for jaw muscle pain for future patients.

Principal Investigator: Estephan Moana-Filho
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: STUDY00020619
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• age between 18-74 years
• pain-free participants OR chronic jaw pain ( > 3 months),
• have a minimum set of teeth present
Exclusion Criteria:

• certain medical conditions (examples: heart disease, diabetes, autism, trigeminal neuralgia)
• any MRI contraindications (examples: metal implants, claustrophobia)
• left-handed only
Conditions: Dentistry
Keywords: Chronic Jaw Pain, Functional Brain Imaging, Temporomandibular Disorders, TMJ
I'm interested
Share via email

NRG-GY028: A PHASE IB AND RANDOMIZED PHASE II TRIAL OF MEGESTROL ACETATE WITH OR WITHOUT IPATASERTIB IN RECURRENT OR METASTATIC ENDOMETRIOID ENDOMETRIAL CANCER

This trial tests the safety, side effects, best dose, and effectiveness of the combination of ipatasertib with megestrol acetate to megestrol acetate alone in women who have endometrial cancer that has come back (recurrent) or has spread to other places in the body (metastatic). Ipatasertib may stop the growth of tumor cells and may kill them by blocking some of the enzymes needed for cell growth. Megestrol acetate lowers the amount of estrogen and also blocks the use of estrogen made by the body. This may help stop the growth of tumor cells that need estrogen to grow. The combination of ipatasertib and megestrol acetate may be more effective in treating endometrial cancer than megestrol acetate alone.

Principal Investigator: Colleen Rivard
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: MMCORC078
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• diagnosis of grade 1 or 2 recurrent or metastatic endometrioid endometrial cancer
• may have received unlimited prior lines of therapy
• walking and able to do all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours
• must be able to swallow and retain oral medications and not have gastrointestinal illnesses that would preclude absorption of medications
• must agree to use adequate contraception during study therapy and for 28 days following the last dose of study therapy
• see link to clinicaltrials.gov for complete inclusion and exclusion criteria
Exclusion Criteria:

• diabetes either requiring insulin therapy or with a baseline fasting glucose > 160 mg/dL and/or high glycosylated hemoglobin A1c (HbA1c) (> 8)
• require chronic corticosteroid therapy of > 10 mg of prednisone per day or an equivalent dose of other anti-inflammatory corticosteroids or immunosuppressant agents for a chronic disease
• history of known or active inflammatory bowel disease (e.g., Crohn disease and ulcerative colitis) or active bowel inflammation (e.g., diverticulitis)
• clinically significant history of liver disease
• women who are pregnant or breast feeding
Conditions: Cancer
I'm interested
Share via email
See this study on ClinicalTrials.gov

OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy With Checkpoint Inhibitor Therapy

This trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who had a complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery.

Principal Investigator: Jocelin Huang
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: MMCORC077
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• walking and able to do all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours
• diagnosis of Triple Negative Breast Cancer (TNBC) without any remaining disease after neoadjuvant chemotherapy with pembrolizumab for at least 6 cycles
• no more than 12 weeks between surgery and starting the trial
• see link to clinicaltrails.gov for complete inclusion and exclusion criteria
Exclusion Criteria:

• stage IV (metastatic) breast cancer
• women who are pregnant or breast feeding
• history of any prior invasive breast cancer in either breast
• active liver disease
• medical conditions that require chronic systemic steroids (>10 mg prednisone daily or equivalent) or any other form of immunosuppressive medications and has required such therapy in the last two years
Conditions: Cancer
Keywords: TNBC, Triple Negative Breast Cancer
I'm interested
Share via email
See this study on ClinicalTrials.gov

Vertical Sleeve Gastrectomy and Lifestyle Modification for the Treatment of Non-Alcoholic Steatohepatitis

This study is comparing the treatment of Non-Alcoholic Steatohepatitis (NASH) with either lifestyle changes or obesity surgery with lifestyle changes.  Participants must be 30-70 years old, have a BMI of 35.0-60.0 kg/m2, have health insurance that will pay for obesity surgery, and be willing to accept either treatment.

Principal Investigator: Sayeed Ikramuddin
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: STUDY00014879
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• ages 30 to 70 years
• diagnosed with NASH with a total NAS >=4 including a ballooning score of at least 1, or diagnosed with T2DM or prediabetes, HbA1c < 9% Body Mass Index (BMI): 35.0-50.0 kg/m2
• willing to accept either surgery or life style changes
• must have insurance with no exclusion for obesity related treatments or management of obesity surgery complications. applies to all participants enrolled in the study
• evidence of liver fat present in the baseline MR images
• suitable for liver biopsy
Exclusion Criteria:

• cardiovascular event (myocardial infarction, acute coronary syndrome, coronary artery angioplasty or bypass, stroke) in the past six months
• pulmonary embolus or thrombophlebitis in the past six months
• cancer diagnosis unless disease free for five years
• alcohol intake more than one drink per day
• other physical or mental health disease (study staff will review)
Conditions: Digestive & Liver Health
Keywords: Bariatric Surgery, NASH, VSG, Clinics and Surgery Center (CSC), fatty liver, gastrectomy, sleeve, sleeve gastrectomy, weight loss
I'm interested
Share via email
See this study on ClinicalTrials.gov

Vibrotactile stimulation of the larynx to treat unexplained chronic cough

This is a study of adults with unexplained chronic cough between 18-80 years old. This study is trying to determine whether a noninvasive vibrotactile stimulation device can help reduce cough symptoms.

Principal Investigator: Stephanie Misono
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: STUDY00012174
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• adults aged 18-80
• more than 8 weeks of non-productive cough
• chest x-ray or chest CT negative (collected as part of routine clinical care); no time limit on imaging (if available)
• clinical impression that untreated or inadequately treated gastroesophageal, pulmonary, and/or sinus or nasal issue is not the reason for the cough
• able to read and speak English
Exclusion Criteria:

• current smoker or quit less than 3 months ago
• infectious cause for cough (e.g., TB, pertussis, COVID)
• history of known or suspected aspiration pneumonia
• recent intubation/neck surgery (within 8 weeks)
• neuromuscular impairment that may affect cough/laryngeal sensation and/or function (e.g., multiple system atrophy, Parkinson, CVA)
• untreated carotid artery disease
• electronic implants (e.g., pacemaker)
• specific medications (study staff will discuss)
• anticipate use of new medications to treat the cough during the period of the study
• currently having speech therapy for cough
• BMI > 40 (for transmission of VTS through soft tissue)
• allergy to adhesives
• drug/alcohol dependency or abuse
• pregnant
• without regular access to wifi and internet
Conditions: Breathing, Lung & Sleep Health, Ear, Nose & Throat
Keywords: chronic cough, cough, larynx, vibrotactile stimulation, Clinics and Surgery Center (CSC)
I'm interested
Share via email
See this study on ClinicalTrials.gov

A multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in idiopathic immune complex mediated membranoproliferative glomerulonephritis (IC-MPGN). (APPARENT)

To evaluate the efficacy and safety of iptacopan compared to placebo in patients with idiopathic immune complex mediated membranoproliferative glomerulonephritis (IC-MPGN)

Principal Investigator: Nattawat Klomjit
Age Group: Not specified
This study is NOT accepting healthy volunteers
IRB Number: STUDY00020504
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• 12 to 60 years old
• diagnosis of idiopathic IC-MPGN as confirmed by kidney biopsy within 12 months prior to starting the study for adults and within 3 years for adolescents
• must have a vaccination against Neisseria meningitidis and Streptococcus pneumoniae infection prior to the start of study treatment
• see link to clinicaltrials.gov for complete Inclusion and Exclusion criteria
Exclusion Criteria:

• have had cell or a solid organ transplantation, including kidney transplantation
• Body mass index (BMI) >38 kg/m2
• Body weight <35 kg (77 pounds)
• additional criteria that study staff will review
Keywords: Clinics and Surgery Center (CSC), Glomerulonephritis, IC-MPGN
I'm interested
Share via email
See this study on ClinicalTrials.gov

Remote State Representation in Early Psychosis (Rem-STEP) (Rem-STEP)

The purpose of the current study is to test the effects of two forms of cognitive training: visual perception training or visual cognitive control training in individuals with early psychosis.

Principal Investigator: Caroline Demro
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: STUDY00020834
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• people who have Schizophrenia, Schizoaffective disorder, Psychosis, Major depressive disorder with psychotic features, or Bipolar disorder with psychotic features
• between ages 18 and 30 except: Alabama & Nebraska 19 to 30 and Mississippi 21 to 30
• able to read and speak English,
• no hospitalizations for mental health issues in the past month
• have access to a computer with internet connection
• permanent resident of the United States
Exclusion Criteria:

• history of substance abuse in the past month
• diagnosed with a neurological disorder
• cognitive training in the past 6 months
Conditions: Mental Health & Addiction
I'm interested
Share via email
See this study on ClinicalTrials.gov

Measurement of Upper Aerodigestive Tract Pressures During Phonation

The purpose of this pilot research study is to test whether a tool called “High-Resolution Manometry” can diagnose laryngeal dystonia (also known as spasmodic dysphonia) and measure how well treatment works. High-Resolution Manometry measures pressures from a small catheter that is passed from your nose into your throat. We believe that pressures in the throat might be different for people with laryngeal dystonia than for people without laryngeal dystonia, or with other types of voice disorders. If we can diagnose laryngeal dystonia shortly after symptoms start, we can get patients the treatment they need sooner.

Principal Investigator: Jesse Hoffmeister
Age Group: 18 years and over
This study is also accepting healthy volunteers
IRB Number: STUDY00015206
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Patients with adductor laryngeal dystonia and:
• experienced improvement in voice quality following injection of botulinum toxin into the thyroarytenoid complex
• received their most-recent injection within 6 months
• age 18-80 years old
• able to read and write in English
• For Healthy Controls:
• age 18-80
• have no known voice problem
• able to read and write in English Patients with Muscle Tension Dysphonia:
• Age 18-80 (age-and sex matched to adductor laryngeal dystonia)
• Diagnosis of primary muscle tension dysphonia by a laryngologist and speech pathologist in the “...absence of current organic vocal fold pathology, [and] without obvious…neurologic etiology.”18
• Able to read and write in English
• Muscle tension dysphonia patients who either haven’t started voice therapy, or for whom symptoms persisted despite voice therapy
Exclusion Criteria:
For people with adductor laryngeal dystonia, Muscle Tension Dysphonia and healthy controls:
• diagnosis of vocal tremor, abductor laryngeal dystonia, any type of vocal fold lesion, or vocal fold paralysis
• known swallowing disorder (oropharyngeal or esophageal), with the exception of transient post-botulinum toxin injection-induced dysphagia
• pregnant
• prisoners
• allergy to topical anesthetic
• cannot fast for 6 hours (4 hour fast prior to study, up to 2 hours to complete the study)
• recent facial trauma
• recent nasal, pharyngeal, laryngeal, or esophageal surgery or obstruction
Conditions: Ear, Nose & Throat
Keywords: Clinics and Surgery Center (CSC)
I'm interested
Share via email

COCOA (COCOA-PAD II)

Few medical treatments are available to improve walking ability in patients with PAD. This research study will help determine the effects of cocoa flavanols on walking ability in people with blockages in their leg arteries. Cocoa flavanols are a type of plant nutrient found in cocoa beans. These supplements are available over-the-counter at drugstores.

Principal Investigator: Diane Treat-Jacobson
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: SITE00001135
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• Age 55 and older
• Presence of peripheral artery disease (PAD). PAD will be defined as either an ABI <= 0.90 at baseline or vascular lab evidence of PAD or angiographic evidence of PAD.
Exclusion Criteria:

• Unable to tolerate study pills
• Inability to walk or requiring a walker
Keywords: cocoa, intercede, pad, peripheral artery disease, prove
I'm interested
Share via email
See this study on ClinicalTrials.gov

Vasomotor symptoms of menopause and cardiovascular disease: What is the link?

Study to examine the physiological responses that occur during a hot flush in postmenopausal women

Principal Investigator: Manda Keller-Ross
Age Group: 18 years and over
This study is also accepting healthy volunteers
IRB Number: STUDY00013742
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Participants must have completed menopause and experience either no menopausal hot flashes or experience three menopausal hot flashes a day.
Exclusion Criteria:

• Reported nicotine/tobacco use within the last six months
• Diabetic or asthmatic
• Diagnosed significant carotid stenosis
• History of significant autonomic dysfunction, heart disease, respiratory disease, or severe neurologic condition such as stroke or traumatic brain injury
• Existing metabolic or endocrine abnormalities
• Use of heart/blood pressure medications that are determined to interfere with study outcomes
• Use of oral contraceptives (or other hormonal contraceptives, including intrauterine devices or contraceptive implants) and/or hormone therapy
• Pregnant or breastfeeding
• Unwilling or unable to refrain from consuming caffeine or alcohol in the 12 hours before visit two and three.
• Unwilling or unable to refrain from vigorous exercise (at least 10 minutes in duration) in the 12 hours before visit two or three
• Unwilling or unable to fast in the eight hours before visit two or three
• Body mass index ≥ 35 kg/m2
Conditions: Blood Disorders, Brain & Nervous System, Women's Health
Keywords: autonomic nervous system, Blood pressure, hot flashes, hypertension, menopause, night sweats
I'm interested
Share via email
See this study on ClinicalTrials.gov

Prospective Evaluation of Chronic Pancreatitis for Epidemiologic and Translational Studies

This study will provide the most accurate and reliable estimates to date on disease progression and clinical events in evolving chronic pancreatitis. We also hope to develop from the results of this study some lab tests that will help us with early diagnosis of chronic pancreatitis and also to discover any genetic factors that may affect your chances of developing chronic pancreatitis.

Principal Investigator: Melena Bellin
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: SITE00001159
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• diagnosis of chronic pancreatitis.
Exclusion Criteria:

• N/A
Conditions: Digestive & Liver Health
Keywords: Chronic Pancreatitis, Pancreatitis
I'm interested
Share via email
See this study on ClinicalTrials.gov

CPDPC16-04: Evaluation of a mixed meal test for Diagnosis and characterization of Type 3c diabeTes mellitus secondary to pancreatic cancer and chronic pancreatitis (DETECT)

Diabetes mellitus is a common condition which is defined by persistently high blood sugar levels. This is a frequent problem that is most commonly due to type 2 diabetes. However, it is now recognized that a small portion of the population with diabetes have an underlying problem with their pancreas, such as chronic pancreatitis or pancreatic cancer, as the cause of their diabetes. Currently, there is no test to identify the small number of patients who have diabetes caused by a primary problem with their pancreas. The goal of this study is to develop a blood test to distinguish these various causes of diabetes.

Principal Investigator: Melena Bellin
Age Group: 18 years and over
IRB Number: SITE00001191
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• 30 to 84 years old
• diabetes diagnosed less than 3 years ago with Pancreatic Cancer or Chronic Pancreatitis or no disease of the pancreas
• OR longstanding diabetes diagnosed 3 or more years ago, with Pancreatic Cancer or Chronic Pancreatitis or no disease of the pancreas
• OR people don't have diabetes but have Pancreatic Cancer or Chronic Pancreatitis or no disease of the pancreas
• see link to clinicaltrials.gov for complete inclusion criteria
Exclusion Criteria:

• currently receiving oral steroid medications
• previous treatment for pancreatic cancer, including chemotherapy or radiation
• on treatment for any cancer
• see link to clinicaltrials.gov for complete exclusion criteria
Conditions: Cancer, Diabetes & Endocrine
Keywords: Chronic Pancreatitis, Diabetes Mellitus Type 3c, Pancreatic Cancer
I'm interested
Share via email
See this study on ClinicalTrials.gov

A phase 3, randomized, double-blind, study to assess efficacy and safety of ianalumab (VAY736) versus placebo in warm autoimmune hemolytic anemia (wAIHA) patients who failed at least one line of treatment (VAYHIA)

The purpose of the study is to see if ianalumab, compared to placebo, is effective and safe for treating wAIHA. A placebo looks like the study drug, ianalumab, but does not contain any active ingredient. Ianalumab belongs to a class of drugs called monoclonal antibodies. Monoclonal antibodies are molecules that can recognize and stick to a specific protein expressed on the cell surface or released free in the body. Participants will receive study drug (ianalumab or placebo) through the vein every 4 weeks (4 doses in total) during the treatment period.

Principal Investigator: Marshall Mazepa, MD
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: STUDY00018783
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• people with documented primary or secondary wAIHA
• had an insufficient response to or relapsed after one or more treatments
• Hemoglobin concentration at screening between 5 g/dL and 10 g/dL and experiencing symptoms of anemia
• dose of supportive medication must be stable for at least 4 weeks
Exclusion Criteria:

• wAIHA due to disease involving bone marrow
• prior use of B-cell depleting therapy (e.g., rituximab) within 12 weeks prior to starting the study
• active viral, bacterial or other infections that require systemic treatment at time of screening, or a history of recurrent clinically significant infection
• positive for hepatitis C virus, hepatitis B surface antigen (HBsAg), or hepatitis B core antibody (HBcAb)
• contact study staff for additional criteria
Conditions: Blood Disorders
Keywords: hemolytic anemia, wAIHA, warm autoimmune hemolytic anemia
I'm interested
Share via email

The women with inflammatory Bowel Disease and Motherhood: A Prospective Registry

This is a prospective questionnaire study that will examine the impact of IBD and its surgical treatments on fertility in women with IBD of reproductive age (18-45). Women with IBD who are attempting to get pregnant within the next year will answer questionnaires about their general, surgical and reproductive health, conception history and sexual partner information. This will help identify risk factors predictive of fertility outcomes and early fetal loss, determine time to conception, and assess efficacy of fertility services including in vitro fertilization.

Principal Investigator: Eugenia Shmidt
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: STUDY00003958
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• age 18-45 years
• diagnosis of inflammatory bowel disease (IBD)
• not currently pregnant or trying to get pregnant
• desire to become pregnant within the next 12 months (may become pregnant while in the study)
Exclusion Criteria:

• prior pelvic surgery, including surgery of the cervix, ovary, uterus or fallopian tubes
• known female sterility
• known male infertility factors in partner
Conditions: Digestive & Liver Health, Women's Health
Keywords: Fertility, IBD, Inflammatory Bowel Disease
I'm interested
Share via email

Impact of a full-mouth electronic toothbrush on indicators of gingivitis and patient perceptions: A randomized clinical trial

The purpose of this trial is to investigate a full-mouth electronic toothbrush (FMET) and foam system compared to a conventional electronic toothbrush (ETB) and dentifrice during a 30-day period to evaluate the impact on clinical indicators of gingivitis, plaque, safety, and patient perceptions.

Principal Investigator: Michelle Arnett
Age Group: 18 years and over
This study is also accepting healthy volunteers
IRB Number: STUDY00022906
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• diagnosis of mild to moderate gingivitis
• minimum of five natural teeth in each quarter of the mouth
• willing to stop all professional oral hygiene care
• willing to stop use of any other dental cleaning aids (dental floss, water flossers, interdental brushes, dental or tooth picks, mouthwash, etc.)
• access to personal email account and a device connected to the internet
Exclusion Criteria:

• aggressive, necrotizing, uncommon periodontal disease, or any uncontrolled periodontal condition
• unable to independently brush teeth
• fixed prosthesis (i.e. implant retained denture), orthodontic appliance or under orthodontic treatment
• pregnant, planning to become pregnant, or unsure of pregnancy status
• use of cigarettes within the last year
Conditions: Rare Diseases, Dentistry
Keywords: Feno Smartbrush, teeth, tooth brush, dental hygiene, gingivitis
I'm interested
Share via email

Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study

This study looks at how certain risk factors (such as age, gender, other medical conditions, and the type of immunotherapy used to treat the cancer) affect whether a patient with a malignant solid tumor will develop mild or serious side effects from the immunotherapy medications. Immunotherapy is the type of treatment that helps the body's immune system fight cancer. In the future, this information may help doctors make better decisions about cancer treatments

Principal Investigator: Puneet Cheema
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: MMCORC082
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• planning to receive Immune Checkpoint Therapy (ICI) for a solid tumor cancer
• if received prior ICI-based therapy must have completed it at least 180 days before starting the study
• must be able to complete Patient-Reported Outcome (PRO) forms in English, Spanish, or French
• see link to clinicaltrials.gov for complete inclusion and exclusion criteria
Conditions: Cancer
Keywords: cancer, ICI, Immune Checkpoint Therapy, solid tumor
I'm interested
Share via email
See this study on ClinicalTrials.gov

Study in Parkinson Disease of Exercise Phase 3 Clinical Trial: SPARX3 (SPARX3)

The purpose of this study is to compare the effects of 2 different levels of exercise intensity and to learn more about effects of aerobic exercise for people with Parkinson’s disease (PD). This study will help us better understand what exercise guidelines should be used in the future.

Principal Investigator: Colum MacKinnon
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: SITE00001163
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• 40 to 80 years old
• diagnosis of idiopathic Parkinson Disease (PD)
• less than 3 years since disease diagnosis
Exclusion Criteria:

• currently being treated with PD medications such as levodopa or dopamine receptor agonists, monoamine oxidase-B (MAO-B) inhibitors, amantadine, or anticholinergics
• expected to start medication within six months of starting the study
• previous use of medications for PD for more than 60 days
• exercising at greater than moderate intensity for 120 minutes or more per week consistently over the last 6 months
• known cardiovascular, metabolic, or renal disease or individuals with major signs or symptoms suggestive of cardiovascular, metabolic, or renal disease without medical clearance to participate in the exercise program
• uncontrolled hypertension (resting blood pressure greater than 150/90 mmHg)
• any medical, mental health, drug or alcohol abuse, assessment or laboratory abnormality that indicates a problem that could limit ability to participate in the exercise program (study staff will evaluate)
• women who are breast-feeding, pregnant, or plan to become pregnant in the next 12 months
• unable to have a brain scan
Conditions: Brain & Nervous System
Keywords: Clinics and Surgery Center (CSC), Parkinson Disease, Parkinson's Disease
I'm interested
Share via email
See this study on ClinicalTrials.gov

AHOD2131, A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma

This phase III trial studies brentuximab vedotin and combination chemotherapy to see how well they work compared to combination chemotherapy alone in treating children and young adults with stage IIB with bulk, stage IIIB, IVA, or IVB Hodgkin lymphoma. Combinations of biological substances in brentuximab vedotin may be able to carry cancer-killing substances directly to Hodgkin lymphoma cells. Chemotherapy drugs, such as doxorubicin hydrochloride, bleomycin sulfate, vincristine sulfate, etoposide, prednisone, and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known if combination chemotherapy is more effective with or without brentuximab vedotin in treating children with high-risk Hodgkin lymphoma.

Principal Investigator: Peter Gordon
Age Group: Not specified
This study is NOT accepting healthy volunteers
IRB Number: SITE00001972
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• 5 to 60 years old
• newly diagnosed untreated confirmed Hodgkin lymphoma
• see link to clinicaltrials.gov for complete inclusion and exclusion criteria
Exclusion Criteria:

• patients with nodular lymphocyte predominant Hodgkin lymphoma
• patients with a history of active interstitial pneumonitis or interstitial lung disease
• administration of prior chemotherapy, radiation, or antibody-based treatment for classic Hodgkin Lymphoma (cHL)
• prior solid organ transplant
• prior allogeneic stem cell transplantation
• women who are pregnant or breast feeding
Conditions: Cancer
Keywords: cHL, Hodgkin Lymphoma, Hodgkin's, Lymphoma
I'm interested
Share via email
See this study on ClinicalTrials.gov

Registry Study of Childhood Cancer in Minnesota

The aim of this study is to obtain newborn blood spots (NBS) and tumor specimens for children and adolescents diagnosed with malignant neoplasms.

Principal Investigator: Erin Marcotte
Age Group: Not specified
This study is also accepting healthy volunteers
IRB Number: STUDY00018811
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• 0 to 21 years of age
• child diagnosed with any type of tumor or cancer
• born in a state that banks newborn blood spots
• able to understand English or Spanish
• parents or siblings may also contribute specimens
Conditions: Cancer
Keywords: blood specimen, cancer, tumor
I'm interested
Share via email

FOLFOX in Combination With Binimetinib as 2nd Line Therapy for Patients With Advanced Biliary Tract Cancers With MAPK Pathway Alterations: A ComboMATCH Treatment Trial

This ComboMATCH treatment trial compares the usual treatment of modified leucovorin, fluorouracil and oxaliplatin (mFOLFOX6) chemotherapy to using binimetinib plus mFOLFOX6 chemotherapy to shrink tumors in patients with biliary tract cancers that have spread to other places in the body (advanced) and had progression of cancer after previous treatments (2nd line setting).

Principal Investigator: Peter Friedell
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
IRB Number: MMCORC081
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• must have enrolled onto clinical trial EAY191 and have been given a treatment assignment to ComboMATCH to EAY191-A6 based on the presence of specific mutation as defined in EAY191
• disease has progressed on gemcitabine based first-line regimen
• adequate contraception is required
• walking and able to do all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours
• see link to clinicaltrials.gov for complete Inclusion and Exclusion criteria
Exclusion Criteria:

• women who are pregnant or breast feeding
• inability to swallow oral medications or impaired gastrointestinal absorption due to gastrectomy or active inflammatory bowel disease
Conditions: Cancer
Keywords: Biliary Cancer, Gall Bladder cancer
I'm interested
Share via email
See this study on ClinicalTrials.gov